2021
DOI: 10.1093/cid/ciab1010
|View full text |Cite
|
Sign up to set email alerts
|

Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network

Abstract: Background Tenofovir alafenamide (TAF), a prodrug of tenofovir (TFV), is included in the majority of the recommended first-line antiretroviral regimens for patients living with HIV, but there are limited data on TAF use in pregnant women. We aimed to examine the plasma pharmacokinetics of TAF and TFV in pregnant women from Europe. Methods Pregnant women living with HIV were included from treatment centers across Europe, and i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(5 citation statements)
references
References 28 publications
0
5
0
Order By: Relevance
“…Placental tenofovir transfer with TAF has separately been reported with a cord blood-tomaternal ratio of 0.81. 19 Plasma tenofovir also was not measured in this study. However, TAF is the predominant moiety that loads target cells, 40 not tenofovir [40][41][42] ; thus, our findings are still important for better understanding TAF PK and efficacy in pregnancy.…”
Section: Discussionmentioning
confidence: 67%
See 3 more Smart Citations
“…Placental tenofovir transfer with TAF has separately been reported with a cord blood-tomaternal ratio of 0.81. 19 Plasma tenofovir also was not measured in this study. However, TAF is the predominant moiety that loads target cells, 40 not tenofovir [40][41][42] ; thus, our findings are still important for better understanding TAF PK and efficacy in pregnancy.…”
Section: Discussionmentioning
confidence: 67%
“…18 The PANNA network reported a similar magnitude of difference between pregnancy and postpartum with pooled pharmacokinetic results from these same dose combinations. 19 TAF AUC tau during pregnancy and postpartum in both arms of the IMPAACT P1026s study were comparable or higher than historical AUC tau in nonpregnant adults. 18 Separately, the International Maternal Pediatric Adolescent AIDS Clinical Trial Network (IMPAACT) 2010/VESTED study showed the combination of dolutegravir with TAF/emtricitabine was associated with lower rates of adverse pregnancy outcomes vs. TDF-containing comparator regimens and was also associated with higher rates of virologic suppression in comparison with efavirenz/TDF/ emtricitabine.…”
Section: Introductionmentioning
confidence: 73%
See 2 more Smart Citations
“…ARV characterization in this compartment has not yet been well understood. While pregnancy and polymorphisms have been established to alter ARV plasma exposure[710], the knowledge of the effect of these factors on ARV disposition in the FGT is very limited. With evidence of an ongoing risk of viral shedding in FGT, even in patients on suppressive antiretroviral therapy (ART) despite undetectable plasma viremia[1113], there is a need to further understand antiretroviral dynamics in this compartment to enable the design of effective therapies.…”
Section: Introductionmentioning
confidence: 99%